14.40
0.45 (3.23%)
| 前收盘价格 | 13.95 |
| 收盘价格 | 13.89 |
| 成交量 | 1,260,802 |
| 平均成交量 (3个月) | 829,673 |
| 市值 | 1,218,766,976 |
| 价格/销量 (P/S) | 67.42 |
| 股市价格/股市净资产 (P/B) | 10.89 |
| 52周波幅 | |
| 利润日期 | 11 Mar 2025 - 17 Mar 2025 |
| 营业利益率 (TTM) | -743.29% |
| 稀释每股收益 (EPS TTM) | -1.62 |
| 季度收入增长率 (YOY) | -23.50% |
| 总债务/股东权益 (D/E MRQ) | 141.69% |
| 流动比率 (MRQ) | 6.08 |
| 营业现金流 (OCF TTM) | -75.07 M |
| 杠杆自由现金流 (LFCF TTM) | -70.25 M |
| 资产报酬率 (ROA TTM) | -40.69% |
| 股东权益报酬率 (ROE TTM) | -181.73% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Liquidia Corporation | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | -4.0 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.50 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 19.49% |
| 机构持股比例 | 54.31% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Caligan Partners Lp | 30 Sep 2024 | 8,118,592 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 29.00 (HC Wainwright & Co., 101.39%) | 购买 |
| 中 | 24.00 (66.67%) | |
| 低 | 19.00 (Needham, 31.94%) | 购买 |
| 平均值 | 24.00 (66.67%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 11.25 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 09 Jan 2025 | 19.00 (31.94%) | 购买 | 12.46 |
| 14 Nov 2024 | 19.00 (31.94%) | 购买 | 10.03 | |
| HC Wainwright & Co. | 14 Nov 2024 | 29.00 (101.39%) | 购买 | 10.03 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ADAIR JASON | - | 14.01 | -445 | -6,234 |
| 累积净数量 | -445 | |||
| 累积净值 ($) | -6,234 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 14.01 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| ADAIR JASON | 职员 | 27 Jan 2025 | 自动卖出 (-) | 445 | 14.01 | 6,234 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合